Tag Archives: NYSE:PFE

Analysts Are Neutral on Top Healthcare Stocks: Pfizer (PFE), Axovant Gene Therapies (AXGT)

Analysts fell to the sidelines weighing in on Pfizer (PFE – Research Report) and Axovant Gene Therapies (AXGT – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks. Pfizer (PFE) In a

J.P. Morgan Sticks to Their Hold Rating for Pfizer (PFE)

J.P. Morgan analyst Chris Schott maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $46. The company’s shares opened today at $43.09. According to TipRanks.com, Schott has 0 stars on 0-5 star

Pfizer (PFE) Receives a Hold from Credit Suisse

Credit Suisse analyst Lorenzo Biasio resumed coverage with a Hold rating on Pfizer (PFE – Research Report) on July 12 and set a price target of $47. The company’s shares closed on Friday at $42.40. According to TipRanks.com, Biasio is

Pfizer (PFE) Receives a Hold from Barclays

Barclays analyst Geoff Meacham maintained a Hold rating on Pfizer (PFE – Research Report) yesterday and set a price target of $41. The company’s shares opened today at $40.30. According to TipRanks.com, Meacham is a 4-star analyst with an average

Pfizer (PFE) Received its Third Buy in a Row

After Credit Suisse and Merrill Lynch gave Pfizer (NYSE: PFE) a Buy rating last month, the company received another Buy, this time from Cantor Fitzgerald. Analyst Louise Chen reiterated a Buy rating on Pfizer today and set a price target

Pfizer (PFE) Gets a Hold Rating from J.P. Morgan

J.P. Morgan analyst Chris Schott maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $46. The company’s shares closed yesterday at $39.38. According to TipRanks.com, Schott has 0 stars on 0-5 star